Medical - Instruments & Supplies
Compare Stocks
5 / 10Stock Comparison
STAA vs LNTH vs MDT vs ISRG vs ABT
Revenue, margins, valuation, and 5-year total return — side by side.
Drug Manufacturers - Specialty & Generic
Medical - Devices
Medical - Instruments & Supplies
Medical - Devices
STAA vs LNTH vs MDT vs ISRG vs ABT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Instruments & Supplies | Drug Manufacturers - Specialty & Generic | Medical - Devices | Medical - Instruments & Supplies | Medical - Devices |
| Market Cap | $1.35B | $5.92B | $99.94B | $161.07B | $151.30B |
| Revenue (TTM) | $239M | $1.55B | $35.48B | $10.58B | $43.84B |
| Net Income (TTM) | $-80M | $279M | $4.61B | $2.98B | $13.98B |
| Gross Margin | 75.6% | 60.5% | 61.9% | 66.3% | 54.0% |
| Operating Margin | -33.3% | 18.8% | 17.9% | 30.5% | 17.8% |
| Forward P/E | 70.2x | 17.5x | 14.1x | 43.8x | 15.9x |
| Total Debt | $38M | $738K | $28.52B | $303M | $15.28B |
| Cash & Equiv. | $153M | $359M | $2.22B | $3.37B | $7.62B |
STAA vs LNTH vs MDT vs ISRG vs ABT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| STAAR Surgical Comp… (STAA) | 100 | 70.3 | -29.7% |
| Lantheus Holdings, … (LNTH) | 100 | 662.8 | +562.8% |
| Medtronic plc (MDT) | 100 | 79.1 | -20.9% |
| Intuitive Surgical,… (ISRG) | 100 | 234.6 | +134.6% |
| Abbott Laboratories (ABT) | 100 | 91.7 | -8.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: STAA vs LNTH vs MDT vs ISRG vs ABT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
STAA ranks third and is worth considering specifically for momentum.
- +40.3% vs ABT's -33.2%
LNTH is the clearest fit if your priority is long-term compounding and sleep-well-at-night.
- 41.9% 10Y total return vs ISRG's 5.5%
- Lower volatility, beta 0.47, Low D/E 0.1%, current ratio 2.70x
MDT carries the broadest edge in this set and is the clearest fit for income & stability and defensive.
- Dividend streak 36 yrs, beta 0.47, yield 3.6%
- Beta 0.47, yield 3.6%, current ratio 1.85x
- Lower P/E (14.1x vs 43.8x)
- 3.6% yield, 36-year raise streak, vs ABT's 2.5%, (3 stocks pay no dividend)
ISRG is the clearest fit if your priority is growth exposure.
- Rev growth 20.5%, EPS growth 22.6%, 3Y rev CAGR 17.4%
- 20.5% revenue growth vs STAA's -23.7%
ABT is the #2 pick in this set and the best alternative if valuation efficiency is your priority.
- PEG 0.53 vs MDT's 36.00
- 31.9% margin vs STAA's -33.6%
- Beta 0.25 vs ISRG's 1.02
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 20.5% revenue growth vs STAA's -23.7% | |
| Value | Lower P/E (14.1x vs 43.8x) | |
| Quality / Margins | 31.9% margin vs STAA's -33.6% | |
| Stability / Safety | Beta 0.25 vs ISRG's 1.02 | |
| Dividends | 3.6% yield, 36-year raise streak, vs ABT's 2.5%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +40.3% vs ABT's -33.2% | |
| Efficiency (ROA) | 175.8% ROA vs STAA's -17.8%, ROIC 6.0% vs -13.2% |
STAA vs LNTH vs MDT vs ISRG vs ABT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
STAA vs LNTH vs MDT vs ISRG vs ABT — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
MDT leads in 2 of 6 categories
LNTH leads 2 • ISRG leads 1 • STAA leads 0 • ABT leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ISRG leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ABT is the larger business by revenue, generating $43.8B annually — 183.1x STAA's $239M. ABT is the more profitable business, keeping 31.9% of every revenue dollar as net income compared to STAA's -33.6%. On growth, ISRG holds the edge at +23.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $239M | $1.5B | $35.5B | $10.6B | $43.8B |
| EBITDAEarnings before interest/tax | -$71M | $347M | $9.4B | $3.8B | $10.9B |
| Net IncomeAfter-tax profit | -$80M | $279M | $4.6B | $3.0B | $14.0B |
| Free Cash FlowCash after capex | -$34M | $372M | $5.4B | $2.8B | $6.9B |
| Gross MarginGross profit ÷ Revenue | +75.6% | +60.5% | +61.9% | +66.3% | +54.0% |
| Operating MarginEBIT ÷ Revenue | -33.3% | +18.8% | +17.9% | +30.5% | +17.8% |
| Net MarginNet income ÷ Revenue | -33.6% | +18.0% | +13.0% | +28.2% | +31.9% |
| FCF MarginFCF ÷ Revenue | -14.4% | +24.0% | +15.2% | +26.8% | +15.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +18.1% | +1.2% | +8.8% | +23.0% | +6.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +47.8% | +76.5% | -11.9% | +18.8% | 0.0% |
Valuation Metrics
MDT leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 11.4x trailing earnings, ABT trades at a 80% valuation discount to ISRG's 57.6x P/E. Adjusting for growth (PEG ratio), ABT offers better value at 0.38x vs MDT's 36.00x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $1.3B | $5.9B | $99.9B | $161.1B | $151.3B |
| Enterprise ValueMkt cap + debt − cash | $1.2B | $5.6B | $126.2B | $158.0B | $159.0B |
| Trailing P/EPrice ÷ TTM EPS | -16.84x | 26.69x | 21.60x | 57.62x | 11.39x |
| Forward P/EPrice ÷ next-FY EPS est. | 70.16x | 17.52x | 14.13x | 43.84x | 15.87x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 36.00x | 2.65x | 0.38x |
| EV / EBITDAEnterprise value multiple | — | 14.61x | 14.32x | 43.62x | 15.83x |
| Price / SalesMarket cap ÷ Revenue | 5.63x | 3.84x | 2.98x | 16.00x | 3.61x |
| Price / BookPrice ÷ Book value/share | 3.93x | 5.72x | 2.08x | 9.17x | 3.18x |
| Price / FCFMarket cap ÷ FCF | — | 16.73x | 19.28x | 64.67x | 23.82x |
Profitability & Efficiency
LNTH leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
ABT delivers a 27.3% return on equity — every $100 of shareholder capital generates $27 in annual profit, vs $-23 for STAA. LNTH carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to MDT's 0.59x. On the Piotroski fundamental quality scale (0–9), ABT scores 7/9 vs STAA's 1/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -23.2% | +24.3% | +9.4% | +16.9% | +27.3% |
| ROA (TTM)Return on assets | -17.8% | +12.4% | +175.8% | +14.8% | +16.6% |
| ROICReturn on invested capital | -13.2% | +30.6% | +6.0% | +15.0% | +9.9% |
| ROCEReturn on capital employed | -11.2% | +17.1% | +7.5% | +16.5% | +10.8% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 5 | 6 | 6 | 7 |
| Debt / EquityFinancial leverage | 0.11x | 0.00x | 0.59x | 0.02x | 0.32x |
| Net DebtTotal debt minus cash | -$115M | -$358M | $26.3B | -$3.1B | $7.7B |
| Cash & Equiv.Liquid assets | $153M | $359M | $2.2B | $3.4B | $7.6B |
| Total DebtShort + long-term debt | $38M | $738,000 | $28.5B | $303M | $15.3B |
| Interest CoverageEBIT ÷ Interest expense | — | 11.72x | 9.08x | — | 19.22x |
Total Returns (Dividends Reinvested)
LNTH leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in LNTH five years ago would be worth $41,420 today (with dividends reinvested), compared to $1,980 for STAA. Over the past 12 months, STAA leads with a +40.3% total return vs ABT's -33.2%. The 3-year compound annual growth rate (CAGR) favors ISRG at 14.4% vs STAA's -26.1% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +15.6% | +35.3% | -18.1% | -19.3% | -28.9% |
| 1-Year ReturnPast 12 months | +40.3% | +13.1% | -2.8% | -15.4% | -33.2% |
| 3-Year ReturnCumulative with dividends | -59.7% | -4.0% | -4.2% | +49.6% | -15.4% |
| 5-Year ReturnCumulative with dividends | -80.2% | +314.2% | -27.7% | +58.7% | -17.9% |
| 10-Year ReturnCumulative with dividends | +273.7% | +4192.5% | +26.5% | +554.2% | +173.7% |
| CAGR (3Y)Annualised 3-year return | -26.1% | -1.4% | -1.4% | +14.4% | -5.4% |
Risk & Volatility
Evenly matched — LNTH and ABT each lead in 1 of 2 comparable metrics.
Risk & Volatility
ABT is the less volatile stock with a 0.25 beta — it tends to amplify market swings less than ISRG's 1.02 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LNTH currently trades 97.8% from its 52-week high vs ABT's 62.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.54x | 0.47x | 0.47x | 1.02x | 0.25x |
| 52-Week HighHighest price in past year | $30.81 | $93.00 | $106.33 | $603.88 | $139.06 |
| 52-Week LowLowest price in past year | $15.64 | $47.25 | $77.16 | $427.84 | $86.15 |
| % of 52W HighCurrent price vs 52-week peak | +88.5% | +97.8% | +73.3% | +75.1% | +62.6% |
| RSI (14)Momentum oscillator 0–100 | 70.0 | 61.2 | 27.3 | 42.4 | 22.9 |
| Avg Volume (50D)Average daily shares traded | 1.2M | 886K | 7.8M | 1.8M | 10.5M |
Analyst Outlook
MDT leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: STAA as "Hold", LNTH as "Buy", MDT as "Buy", ISRG as "Buy", ABT as "Buy". Consensus price targets imply 47.9% upside for ABT (target: $129) vs -15.9% for STAA (target: $23). For income investors, MDT offers the higher dividend yield at 3.57% vs ABT's 2.52%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $22.95 | $101.00 | $109.50 | $622.60 | $128.71 |
| # AnalystsCovering analysts | 15 | 17 | 49 | 55 | 41 |
| Dividend YieldAnnual dividend ÷ price | — | — | +3.6% | — | +2.5% |
| Dividend StreakConsecutive years of raises | — | 0 | 36 | — | 11 |
| Dividend / ShareAnnual DPS | — | — | $2.78 | — | $2.19 |
| Buyback YieldShare repurchases ÷ mkt cap | +0.5% | +5.1% | +3.2% | +1.4% | +0.9% |
MDT leads in 2 of 6 categories (Valuation Metrics, Analyst Outlook). LNTH leads in 2 (Profitability & Efficiency, Total Returns). 1 tied.
STAA vs LNTH vs MDT vs ISRG vs ABT: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is STAA or LNTH or MDT or ISRG or ABT a better buy right now?
For growth investors, Intuitive Surgical, Inc.
(ISRG) is the stronger pick with 20. 5% revenue growth year-over-year, versus -23. 7% for STAAR Surgical Company (STAA). Abbott Laboratories (ABT) offers the better valuation at 11. 4x trailing P/E (15. 9x forward), making it the more compelling value choice. Analysts rate Lantheus Holdings, Inc. (LNTH) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — STAA or LNTH or MDT or ISRG or ABT?
On trailing P/E, Abbott Laboratories (ABT) is the cheapest at 11.
4x versus Intuitive Surgical, Inc. at 57. 6x. On forward P/E, Medtronic plc is actually cheaper at 14. 1x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Abbott Laboratories wins at 0. 53x versus Medtronic plc's 36. 00x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — STAA or LNTH or MDT or ISRG or ABT?
Over the past 5 years, Lantheus Holdings, Inc.
(LNTH) delivered a total return of +314. 2%, compared to -80. 2% for STAAR Surgical Company (STAA). Over 10 years, the gap is even starker: LNTH returned +41. 9% versus MDT's +26. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — STAA or LNTH or MDT or ISRG or ABT?
By beta (market sensitivity over 5 years), Abbott Laboratories (ABT) is the lower-risk stock at 0.
25β versus Intuitive Surgical, Inc. 's 1. 02β — meaning ISRG is approximately 310% more volatile than ABT relative to the S&P 500. On balance sheet safety, Lantheus Holdings, Inc. (LNTH) carries a lower debt/equity ratio of 0% versus 59% for Medtronic plc — giving it more financial flexibility in a downturn.
05Which is growing faster — STAA or LNTH or MDT or ISRG or ABT?
By revenue growth (latest reported year), Intuitive Surgical, Inc.
(ISRG) is pulling ahead at 20. 5% versus -23. 7% for STAAR Surgical Company (STAA). On earnings-per-share growth, the picture is similar: Abbott Laboratories grew EPS 133. 6% year-over-year, compared to -295. 1% for STAAR Surgical Company. Over a 3-year CAGR, LNTH leads at 18. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — STAA or LNTH or MDT or ISRG or ABT?
Abbott Laboratories (ABT) is the more profitable company, earning 31.
9% net margin versus -33. 6% for STAAR Surgical Company — meaning it keeps 31. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ISRG leads at 29. 3% versus -19. 2% for STAA. At the gross margin level — before operating expenses — STAA leads at 73. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is STAA or LNTH or MDT or ISRG or ABT more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Abbott Laboratories (ABT) is the more undervalued stock at a PEG of 0. 53x versus Medtronic plc's 36. 00x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Medtronic plc (MDT) trades at 14. 1x forward P/E versus 70. 2x for STAAR Surgical Company — 56. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ABT: 47. 9% to $128. 71.
08Which pays a better dividend — STAA or LNTH or MDT or ISRG or ABT?
In this comparison, MDT (3.
6% yield), ABT (2. 5% yield) pay a dividend. STAA, LNTH, ISRG do not pay a meaningful dividend and should not be held primarily for income.
09Is STAA or LNTH or MDT or ISRG or ABT better for a retirement portfolio?
For long-horizon retirement investors, Abbott Laboratories (ABT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
25), 2. 5% yield, +173. 7% 10Y return). Both have compounded well over 10 years (ABT: +173. 7%, ISRG: +554. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between STAA and LNTH and MDT and ISRG and ABT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: STAA is a small-cap quality compounder stock; LNTH is a small-cap quality compounder stock; MDT is a mid-cap income-oriented stock; ISRG is a mid-cap high-growth stock; ABT is a mid-cap deep-value stock. MDT, ABT pay a dividend while STAA, LNTH, ISRG do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.